Formulation and in vitro evaluation of bilayer tablets of bicalutamide and koenimbine

Abstract

This work is about developing, optimizing, and testing In vitro a bilayer tablet with Koenimbine (KNB) in the immediate release layer and bicalutamide (BCT) in the sustained release layer. Sodium starch glycolate is used as a super disintegrant in the immediate release layer, and the hydrophilic matrix HPMC-K100 is used in the sustained release layer. Bilayer tablet showed initial burst effect to provide dose of immediate release layer Koenimbine to control the acid secretion level and the sustained release of bicalutamide for 24 hours. The prepared bilayer tablet was tested for its precompression parameters, physical properties like hardness, friability, uniformity of weight, uniformity of drug content, swelling index, and In-vitro drug release. In 45 minutes, 100.37 ± 0.35 percent of the Koenimbine in the immediate release layer was found to be released. In 24 hours, 98.32% of the bicalutamide in the layer with slow release was found to have been released. Koenimbine makes bicalutamide work better. So, bilayer tablets of koenimbine and bicalutamide were used to get more patients to take their medicine so that prostate cancer could be treated better.